<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04007809</url>
  </required_header>
  <id_info>
    <org_study_id>DIATAG</org_study_id>
    <nct_id>NCT04007809</nct_id>
  </id_info>
  <brief_title>Phenotypic and Genotypic Characterization of New-onset Type I Diabetes</brief_title>
  <acronym>DIATAG</acronym>
  <official_title>Phenotypic and Genotypic Characterization of a Cohort of Pediatric Patients With New-onset Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FNRS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BESPEED</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of DIATAG study is the identification of biomarkers of T1D evolution in a pediatric
      cohort.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 1 diabetes (T1D) is a common chronic disease in childhood. Clinical presentation at
      onset of T1D can vary among patients from long-standing diabetes triad symptoms (polyuria,
      polydipsia and weight loss) to coma and ketoacidosis. The initial clinical presentation of
      T1D was shown to have long-term influence on glycemic control of the patient. The
      investigators initiated a collaborative consortium including six pediatric clinics in Belgium
      to better characterize new-onset T1D patients.

      Hypothesis :

        1. Different subgroups of T1D patients might exist, underlying different physiopathology of
           T1D :

             -  The investigators will first investigate the presence of biomarkers in different
                fluids (e.g. urine, blood, feces,...).

             -  The investigators will correlate results with clinical parameters of glycemic
                control. Dynamic tests (HOMA and stimulated C peptide) will be realized at 2
                defined time points of the follow-up.

        2. Glucose variability can be influenced by external factors (e.g. diet, physical activity,
           Quality of Life (QoL),...) The investigators will evaluate those external factors using
           approved questionnaires. They will presented to the patient and its parents at 2 defined
           time points.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of T1D subgroups by using follow-up of clinical parameters : weight in kilograms</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>weight in kilograms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of T1D subgroups by using follow-up of clinical parameters : Height in centimeter</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>Height in centimeter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of T1D subgroups by using follow-up of clinical parameters : Body mass index (kg/m²)</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>Body mass index (kg/m²)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of T1D subgroups by using follow-up of clinical parameters : glycemic variability (%)</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>glycemic variability (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Follow-up of laboratory results - glycemia (mg/dL)</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>glycemia (mg/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Follow-up of laboratory results - Insulin (mUI/L)</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>Insulin (mUI/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Follow-up of laboratory results - HbA1C (%)</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>HbA1C (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Follow-up of laboratory results - C-peptide (mUI/L)</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>C-peptide (mUI/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation and follow-up of diet, physical activity, quality of life using validated questionnaires.</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>Composite of Physical Activity Questionnaire (PAQ), DisabKids, Health Behaviour in School-aged Children (HBSC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation and follow-up of physical activity</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>Physical Activity Questionnaire (PAQ). This questionnaire consists of 8 items. Once you have a value from 1 to 5 for each of the 8 items (items 1 to 8) used in the Physical Activity composite score, you simply take the mean of these 8 items, which results in the final PAQ activity summary score.
A score of 1 indicates low physical activity, wheareas a score of 5 indicates high physical activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation and follow-up of quality of life: DisabKids Questionnaires</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>DisabKids Questionnaires. The paper version of DISABKIDS consisted of the generic health related quality of life questionnaire for 8- to 18-year-olds (37 items) and the DISABKIDS Diabetes module (10 items). The questionnaire is designed to measure health related quality of life of children with a chronic medical condition. Questions are answered on a Likert type scale of 1-5 points. Lower scores correspond to better quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Production of prediction model of β-cell mass evolution</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>Composite score using clinical parameters and laboratory results</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Type1diabetes</condition>
  <arm_group>
    <arm_group_label>New-onset Type 1 diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <description>Every patients will undergo stimulated C peptide test. Glucagon will be administered using intravenous route (0,03 mg/kg, max 1mg).</description>
    <arm_group_label>New-onset Type 1 diabetes</arm_group_label>
    <other_name>Glucagen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 1 diabetes de novo according to American Diabetes Association criteria:

               1. Polyuria, polydipsia, weight loss ± ketoacidosis

               2. Fasting blood glucose ≥126 mg/dL AND/OR blood glucose ≥200 mg/dL at the 120th
                  minute of an Oral Glucose Tolerance Test (OGTT) AND/OR HbA1c ≥6.5% AND/OR a
                  patient with symptoms of hyperglycemia/hyperglycemic crisis (see 8. a. 2.) with
                  random blood glucose ≥200 mg/dL.

               3. Presence in the serum of one or more anti-islet autoantibodies (anti-insulin,
                  anti-IA2, anti-GAD65, anti-ZnT8)

          2. Age between 6 months and 18 years.

          3. Male or female.

          4. Positive for one or more autoantibodies typically associated with Type 1 Diabetes
             (TD1).

          5. Free written and oral consent.

        Exclusion Criteria:

          1. Children under 6 months of age.

          2. Treatment that interferes with insulin secretion and insulin sensitivity (e. g.
             sulfonylureas, diazoxide, somatostatin, methylxanthine derivatives, corticosteroids,
             biguanide, incretins).

          3. Presence of celiac disease (diagnosis based on pathological duodenal biopsy), recently
             diagnosed (within 1 month), at the time of inclusion.

          4. Autoimmune/auto-inflammatory disease (other than type 1 diabetes) or active malignant
             disease present at inclusion.

          5. Obesity defined by a Body Mass Index (BMI) with a z-score &gt;+3 Standard Deviation.

          6. Hepatic, renal or adrenal insufficiency.

          7. History of spinal cord allograft.

          8. History of post-hemolytic-uremic diabetes.

          9. Absence of anti-pancreatic islet auto-antibodies.

         10. Dysmorphic with suspicion of underlying genetic syndrome.

         11. Participation in another study within the previous 3 months, with administration of
             blood derivatives or potentially immunomodulating treatments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philippe A Lysy, MD, PhD</last_name>
    <phone>0032 2 764 13 70</phone>
    <email>philippe.lysy@uclouvain.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivier Polle, MD</last_name>
    <phone>0032 2 764 13 70</phone>
    <email>olivier.polle@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Lysy</last_name>
      <email>philippe.lysy@uclouvain.be</email>
    </contact>
    <contact_backup>
      <last_name>Olivier Polle</last_name>
      <email>olivier.polle@uclouvain.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 3, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>July 9, 2019</last_update_submitted>
  <last_update_submitted_qc>July 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 1 diabetes</keyword>
  <keyword>children</keyword>
  <keyword>biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

